Shaily Engineering Plastics Ltd (BOM:501423) (Q1 2027) Earnings Call Highlights: Healthcare ...

Negative Points

• Consumer segment revenue declined 24% YoY to INR 116 crores due to soft demand in home furnishings across Europe and the US.

• Gross margin declined sequentially due to increased commodity prices, elevated freight costs, and premium freight incidents from geopolitical tensions in West Asia.

• Machine utilization remains low at 50.2%, indicating significant idle capacity despite gradual improvement.

• New production line for pen injectors is still facing efficiency issues, with only a 9% speed improvement and additional equipment pending, limiting near-term output.

• Export share dropped to 58% from 76% YoY, reflecting a shift in revenue mix and potential over-reliance on domestic pharma customers for healthcare exports.

• The company faces potential pricing pressure from Chinese competitors offering copycat products at lower prices, though management downplays the threat.

• Uncertainty in the consumer segment persists, with management expecting no growth in the current year and unable to provide a clear outlook.

• The UK subsidiary experienced a revenue drop due to timing issues in milestone invoicing, which may affect quarterly results.

• The Abu Dhabi facility is still in early stages, with only 50-55% capacity commitments secured and production not expected until end of FY28.

• The company is not providing specific guidance on consumer electronics or semiconductor revenue timelines, creating uncertainty for investors.

Q & A Highlights

Q: Can we know how many pens we have done in Q1 FY27, and what is the ballpark proportion of insulin and GLP-1 in that? A: Amit Sanghvi, Managing Director, stated that all delivery devices put together totaled close to 9 million units in the first quarter. He noted that GLP-1 devices make up roughly 50% to 60% of the mix, with the remainder being insulin plus other therapies.

Q: What is the status of the new pen line that was set up, and what is the timeline for the next line? A: Amit Sanghvi, Managing Director, said they have increased speed on the existing line by about 9%, but it still needs further improvement. Additional equipment is expected to drive another 30% jump before the end of the current quarter. For the second line, they have changed strategy to ramp up efficiency to 80% plus at the supplier's site before shipping, ensuring a smoother installation and faster time to optimal efficiency.

Q: Given the 9 million devices shipped in Q1 and the planned capacity expansion, is it fair to believe you will beat the full-year guidance of 36 million devices? A: Amit Sanghvi, Managing Director, confirmed that while it is an evolving situation due to partner supply chain issues, they should be able to go beyond the 36 million device guidance for the year.

Q: Can you provide an update on the consumer electronics plant and the semiconductor tray business? A: Amit Sanghvi, Managing Director, confirmed that commercial supplies have started for the consumer electronics customer, and they have been awarded five new components from a new customer expected to go into supply before the end of the financial year. The location for the new plant has been secured, with a formal update expected next quarter. Sanjay Shah, Chief Strategy Officer, added that semiconductor tray revenue is expected to start in Q4 FY27, with an initial investment of about INR 5 crores in the existing facility.

Q: How should we look at the gross margin decline sequentially, and what is the pricing strategy for GLP-1 devices given potential Chinese competition? A: Sanjay Shah, Chief Strategy Officer, attributed the gross margin decline to increased commodity prices and freight costs due to the geopolitical situation, with pass-through mechanisms delayed. He expects margins to normalize by Q3. Amit Sanghvi, Managing Director, clarified that contracts are not cost-plus but volume and market-driven with annual price reviews. He noted that Chinese competitors are pricing around $1.50-$1.70 for copycat products, while Shaily's pricing is above $2, and they are not overly concerned about the competition.

Q: How comfortable are you with the guidance of 36 million devices given the issues faced by a key pharmaceutical partner (Dr. Reddy's) in Canada and Brazil? A: Amit Sanghvi, Managing Director, stated that despite the partner's issues, Shaily actually needs to supply more to fill the gap in the market. He confirmed that they remain confident in the guidance, as they have approvals in various markets and other partners are selling the product.

Q: Can you provide color on the conversations with customers regarding the Abu Dhabi capacity? A: Amit Sanghvi, Managing Director, said that roughly 50% to 55% of the Abu Dhabi capacity has commitments and indications. The plant is expected to start commercial sales by the end of FY28, positioning it for markets opening up in Europe in 2028 and globally in 2030-31.

Q: What is the scale you can reach in the consumer electronics vertical in the next two to three years? A: Amit Sanghvi, Managing Director, indicated that they project reaching $10 million in revenue from this vertical within 24 to 30 months. Sanjay Shah, Chief Strategy Officer, noted they are building up the portfolio and adding products, with an investment of INR 80-100 crores planned for the new facility.

Q: Can you share details on the newly appointed heads of business development for Europe and North America, and their key roles? A: Amit Sanghvi, Managing Director, shared that the European head has a master's from HEC Paris and long experience in medical devices and drug delivery. The U.S. head comes from competitors like West, Phillips, Medtize, and Haselmeier. Their roles are end-to-end, responsible for liaising with innovators, scoping projects, and meeting customer objectives. He expressed confidence in securing a partnership with a major global pharmaceutical company over the next four to six quarters.

Q: What is the status of the development of the emergency use auto-injector, reusable auto-injector, and on-body injector platforms? A: Amit Sanghvi, Managing Director, said the reusable auto-injector is advanced and will be showcased at CPHI in Milan. The emergency use auto-injector, based on the Tobii platform with key design changes, is expected to be completed by the end of 2027, requiring 99.999% reliability. The on-body injector is in partnership discussions, with a delivery range of 3ml to 15ml. He noted these are high-value, high-margin therapies, with device costs ranging from $6-$10 for emergency use to $15-$35 for on-body injectors.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .